Cue Biopharma, Inc. (NASDAQ:CUE – Get Free Report) insider Sumita Ray sold 8,829 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $30.09, for a total transaction of $265,664.61. Following the transaction, the insider directly owned 118,545 shares in the company, valued at $3,567,019.05. This trade represents a 6.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Cue Biopharma Stock Down 19.2%
Shares of NASDAQ CUE traded down $6.56 during midday trading on Monday, reaching $27.64. 305,202 shares of the company’s stock traded hands, compared to its average volume of 363,425. The stock’s 50 day simple moving average is $29.50 and its 200-day simple moving average is $146.00. Cue Biopharma, Inc. has a one year low of $4.97 and a one year high of $45.50. The company has a market cap of $116.09 million, a price-to-earnings ratio of -1.02 and a beta of 2.47.
Cue Biopharma (NASDAQ:CUE – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The business had revenue of $7.88 million for the quarter, compared to analysts’ expectations of $3.00 million. Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 482.58%.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on CUE
Hedge Funds Weigh In On Cue Biopharma
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. purchased a new stake in Cue Biopharma during the 2nd quarter worth approximately $83,000. BlackRock Inc. purchased a new stake in shares of Cue Biopharma during the second quarter valued at $1,824,000. Boothbay Fund Management LLC increased its position in shares of Cue Biopharma by 15.3% in the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock valued at $215,000 after acquiring an additional 93,333 shares during the period. Stifel Financial Corp raised its stake in Cue Biopharma by 25.4% in the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in Cue Biopharma during the 3rd quarter worth about $62,000. 35.04% of the stock is owned by hedge funds and other institutional investors.
Cue Biopharma Company Profile
Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.
Featured Articles
- Five stocks we like better than Cue Biopharma
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
